5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: A cluster-randomised, double-blind, placebo-controlled trial
MetadataShow full item record
Background: Efficacy and safety of a two-dose regimen of bivalent killed whole-cell oral cholera vaccine (Shantha Biotechnics, Hyderabad, India) to 3 years is established, but long-term efficacy is not. We aimed to assess protective efficacy up to 5 years in a slum area of Kolkata, India. Methods: In our double-blind, cluster-randomised, placebo-controlled trial, we assessed incidence of cholera in non-pregnant individuals older than 1 year residing in 3933 dwellings (clusters) in Kolkata, India. We randomly allocated participants, by dwelling, to receive two oral doses of modified killed bivalent whole-cell cholera vaccine or heat-killed Escherichia coli K12 placebo, 14 days apart. Randomisation was done by use of a computer-generated sequence in blocks of four. The primary endpoint was prevention of episodes of culture-confirmed Vibrio cholerae O1 diarrhoea severe enough for patients to seek treatment in a health-care facility. We identified culture-confirmed cholera cases among participants seeking treatment for diarrhoea at a study clinic or government hospital between 14 days and 1825 days after receipt of the second dose. We assessed vaccine protection in a per-protocol population of participants who had completely ingested two doses of assigned study treatment. Findings: 69 of 31932 recipients of vaccine and 219 of 34968 recipients of placebo developed cholera during 5 year follow-up (incidence 2·2 per 1000 in the vaccine group and 6·3 per 1000 in the placebo group). Cumulative protective efficacy of the vaccine at 5 years was 65% (95% CI 52-74; p < 0·0001), and point estimates by year of follow-up suggested no evidence of decline in protective efficacy. Interpretation: Sustained protection for 5 years at the level we reported has not been noted previously with other oral cholera vaccines. Established long-term efficacy of this vaccine could assist policy makers formulate rational vaccination strategies to reduce overall cholera burden in endemic settings. Funding: Bill & Melinda Gates Foundation and the governments of South Korea and Sweden. © 2013 Elsevier Ltd.
Showing items related by title, author, creator and subject.
Qadri, F.; Wierzba, T.; Ali, Mohammed; Chowdhury, F.; Khan, A.; Saha, A.; Khan, I.; Asaduzzaman, M.; Akter, A.; Khan, A.; Begum, Y.; Bhuiyan, T.; Khanam, F.; Chowdhury, M.; Islam, T.; Chowdhury, A.; Rahman, A.; Siddique, S.; You, Y.; Kim, D.; Siddik, A.; Saha, N.; Kabir, A.; Cravioto, A.; Desai, S.; Singh, A.; Clemens, J. (2016)Copyright © 2016 Massachusetts Medical Society. All rights reserved. Background: A single-dose regimen of the current killed oral cholera vaccines that have been prequalified by the World Health Organization would make ...
Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trialQadri, F.; Ali, Mohammed; Lynch, J.; Chowdhury, F.; Khan, A.; Wierzba, T.; Excler, J.; Saha, A.; Islam, M.; Begum, Y.; Bhuiyan, T.; Khanam, F.; Chowdhury, M.; Khan, I.; Kabir, A.; Riaz, B.; Akter, A.; Khan, A.; Asaduzzaman, M.; Kim, D.; Siddik, A.; Saha, N.; Cravioto, A.; Singh, A.; Clemens, J. (2018)© 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: A single-dose regimen of inactivated whole-cell oral cholera vaccine (OCV) is attractive because it ...
Efficacy of a Low-Cost, inactivated Whole-Cell oral cholera vaccine: Results from 3 years of Follow-Up of a randomized, controlled trialSur, D.; Kanungo, S.; Sah, B.; Manna, B.; Ali, Mohammed; Paisley, A.; Niyogi, S.; Park, J.; Sarkar, B.; Puri, M.; Kim, D.; Deen, J.; Holmgren, J.; Carbis, R.; Rao, R.; van Thu, N.; Han, S.; Attridge, S.; Donner, A.; Ganguly, N.; Bhattacharya, S.; Nair, G.; Clemens, J.; Lopez, A. (2011)Background: Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical ...